// App-Quantinova.ai

: MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Researchers

Presenter

  • Marcos De Lima

Principal Investigators

  • Florent Malard

  • Eduardo Olavarria

  • Estefania Perez Lopez

  • Michael Medinger

  • Elisabeth Kueenburg

  • Malika Souquieres

  • Julien Cachat

  • Christos Stylianou

  • Patrice Chevallier

Medical Centers

  • HOSPITAL UNIVERSITARIO, SALAMANCA, Spain

  • Hammersmith Hospital, Imperial College London, London, United Kingdom

  • University Hospital Basel, Basel, Switzerland

  • Priothera SAS, Saint-Louis, France

  • Hematology Department, Nantes University Hospital, Nantes, France

  • Hospital Saint-Antoine, Paris, France

  • ClinBAY, Limassol, Cyprus

  • The Ohio State University, Columbus, OH

Locations

  • Spain

  • Switzerland

  • France

  • Cyprus

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Acute promyelocytic leukemia

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclosporine A

  • Methotrexate

  • Tacrolimus

  • KRP203

  • Allopurinol

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Unblinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved